John Krauss, MD
Medical Oncology · Ann Arbor, MINPI 1396745014
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,334 of the $2,801 with a category attached, or 83.3%. F. Hoffmann-la Roche AG accounts for 83.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $2,350 and has fallen 92.9% since, to $168 in 2025.
Across 12 payments — averaging $233.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$2K
- Pfizer$230
- Novartis$161
- Janssen Research & Development, LLC$38
- Incyte Corporation$22
- Astellas Pharma US Inc$16
Across 203 payments — averaging $30,565 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$4.7M
- E.r. Squibb & Sons, L.L.C.$219K
- Novartis$211K
- AbbVie$210K
- AstraZeneca$168K
- Pfizer$160K
- plus $540K from 8 others
What the payments were for
- Speaking & faculty fees$2,33483%
- Food & beverage$45216%
- Education$161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 6 | $2,334 |
| Pfizer | 2 | $230 |
| Novartis | 1 | $161 |
| Janssen Research & Development, LLC | 1 | $38 |
| Incyte Corporation | 1 | $22 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$2,334
- BRAFTOVI$130
- PREVNAR 20$100
How this compares
$2,801 in reported general payments places this provider in the 55th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 13 | $311,293 |
| ImbruvicaIbrutinib | 12 | $196,670 |
| LonsurfTrifluridine/Tipiracil Hcl | 14 | $193,382 |
| EliquisApixaban | 39 | $34,378 |
| Doxycycline Hyclate | 28 | $924 |
| Anastrozole | 20 | $837 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 40 | $724 |
| Olanzapine | 31 | $463 |
| Omeprazole | 26 | $438 |
| Potassium Chloride | 21 | $424 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 15 | $357 |
| Triamcinolone Acetonide | 25 | $281 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 24 | $279 |
| Ondansetron Hcl | 31 | $242 |
| Gabapentin | 16 | $207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $230 | $34,37839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 170 medical oncology providers in Michigan.
Other medical oncology in Ann Arbor
- Harry ErbaAnn Arbor$1.1M
- Frank WeinbergAnn Arbor$195K
- Francis WordenAnn Arbor$142K
- Maha HussainAnn Arbor$114K
- Moshe TalpazAnn Arbor$83K
- Vaibhav SahaiAnn Arbor$80K
- Howard TerebeloAnn Arbor$47K
- Angel QinAnn Arbor$41K
- Erin CobainAnn Arbor$38K
- Phillip PalmbosAnn Arbor$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.